Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
06 sept. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
Achillion to Present at Two Upcoming Investor Conferences
01 sept. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
09 août 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports Second Quarter 2016 Financial Results
04 août 2016 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
13 juil. 2016 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK...
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
12 juil. 2016 07h00 HE
|
Akari Therapeutics, Plc
NEW YORK and LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
10 juin 2016 03h30 HE
|
Achillion Pharmaceuticals, Inc.
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 - - Results support initiation...
Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference
26 mai 2016 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 26, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced that Gur Roshwalb, MD, Chief...
Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome
23 mai 2016 07h10 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 23, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines...
Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated
19 mai 2016 07h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 19, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that data on Coversin...